4/14
08:15 am
cero
CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial
Medium
Report
CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial
3/30
08:46 am
cero
CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial [Yahoo! Finance]
Low
Report
CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial [Yahoo! Finance]
3/30
08:15 am
cero
CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial
Low
Report
CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial
3/11
08:32 am
cero
CERo Therapeutics Provides Shareholder Update [Yahoo! Finance]
Low
Report
CERo Therapeutics Provides Shareholder Update [Yahoo! Finance]
3/11
08:15 am
cero
CERo Therapeutics Provides Shareholder Update
Low
Report
CERo Therapeutics Provides Shareholder Update
2/17
08:00 am
cero
CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors
High
Report
CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors
2/4
09:27 am
cero
CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient [Yahoo! Finance]
Medium
Report
CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient [Yahoo! Finance]
2/4
09:05 am
cero
CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient
Medium
Report
CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient